NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for F...(s except share and per share data) ...),Health

Date:11/5/2009

s, except share and per share data) (unaudited) September 30, December 31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash equivalents $22,095 $26,642 Accounts receivable, net 11,668 11,886 Inventory 27,754 30,862 Prepaid expenses and other current assets 2,073 2,011 ----- ----- Total current assets 63,590 71,401 Property and equipment, net 10,630 12,254 Field equipment, net 25,152 30,445 Deferred cost of revenues 23,592 23,711 Intangible assets, net 28,907 31,004 Goodwill 42,698 42,698 Other assets 901 553 --- --- Total assets $195,470 $212,066 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $17,341 $17,183 Accrued expenses 10,652 10,746 Current portion of long-term debt 62 9,110 -- ----- Total current liabilities 28,055 37,039 Deferre
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress